XENEISOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XENEISOL (XENEISOL).
XENEISOL is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
| Metabolism | Primarily metabolized by hepatic cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, to active metabolite NORXENEISOL. |
| Excretion | Primarily hepatic metabolism followed by renal excretion of metabolites: 70% renal, 20% biliary/fecal, 10% unchanged in urine. |
| Half-life | Terminal elimination half-life is 4.5 hours (range 3.5-6 hours) in adults; prolonged to 8-12 hours in hepatic impairment. |
| Protein binding | 92-96% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2 L/kg (0.8-1.6 L/kg), indicating extensive extravascular distribution. |
| Bioavailability | Oral: 75% (first-pass metabolism reduces bioavailability); intravenous: 100%. |
| Onset of Action | Intravenous: 2-5 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 2-4 hours; Oral: 4-6 hours. Duration is dose-dependent and may be extended with repeated dosing. |
10 mg orally once daily, titrated to a maximum of 20 mg daily based on response and tolerability.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-59 mL/min: 5 mg orally once daily; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg orally once daily; Child-Pugh C: contraindicated. |
| Pediatric use | Safety and efficacy not established; use not recommended. |
| Geriatric use | Initial dose of 5 mg orally once daily due to increased sensitivity and renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XENEISOL (XENEISOL).
| Breastfeeding | XENEISOL is excreted into human milk. M/P ratio: 0.8. Theoretical risk of neonatal toxicity and cardiovascular effects. Breastfeeding is contraindicated during therapy and for 2 weeks after last dose. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, particularly neural tube defects and cardiac anomalies, in animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Late third trimester: Potential neonatal complications including persistent pulmonary hypertension and renal impairment. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
["Concurrent use with MAOIs or within 14 days of MAOI therapy","Concurrent use with pimozide","Known hypersensitivity to XENEISOL or any excipient"]
| Precautions | ["Serotonin syndrome with co-administration of other serotonergic drugs","Discontinuation syndrome upon abrupt cessation","Increased risk of bleeding with NSAIDs or anticoagulants","Hyponatremia in elderly or volume-depleted patients","Activation of mania/hypomania"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes. Serial fetal ultrasound for growth, amniotic fluid volume, and ductus arteriosus patency. Non-stress test or biophysical profile weekly after 28 weeks. Neonatal assessment for renal function and pulmonary hypertension at birth. |
| Fertility Effects | Reversible impairment of spermatogenesis in males; reduced ovarian reserve in females based on animal data. May delay time to conception. Contraceptive counseling recommended. |